Brief by Shorts91 Newsdesk / 06:37am on 05 May 2024,Sunday India Global
Cipla and Glenmark, two Indian pharmaceutical companies, are recalling products from the US market due to manufacturing issues. Cipla is recalling 59,244 packs of inhalation solution used to treat asthma and other lung diseases due to underfilling. Glenmark is recalling 3,264 bottles of blood pressure medication for failing to meet dissolution standards. Both recalls were initiated in March and April, respectively, and are classified as Class II, indicating temporary or reversible adverse health consequences. The US Food and Drug Administration (FDA) announced the recalls, which aim to ensure consumer safety.
